The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.
In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.
A new Alzheimer's drug isn't reaching many patients. Doctors say reasons include its high cost, and lingering questions about its effectiveness.
Weeks after the Food and Drug Administration approved the Alzheimer's drug Aduhelm, doctors are struggling to figure out who should get the drug and how to use it safely.